Cytomegalovirus glycoprotein B genotypes and central nervous system disease in AIDS patients

✍ Scribed by Lucy S. Vilas Boas; Vanda A. Ueda F. de Souza; Augusto C. Penalva de Oliveira; Ana T. Rodriguez Viso; Anderson M. Nascimento Filho; Maria C. Nascimento; Cláudio S. Pannuti

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 66 KB
• Volume: 71
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.10488

✦ Synopsis

Abstract

To investigate any association between cytomegalovirus glycoprotein B (CMV gB) subtypes and central nervous system (CNS) disease in AIDS patients, proportions of different gB genotypes detected in AIDS patients with CNS disease were compared with the gB genotypes detected in AIDS patients with no neurological disorder. The patients were matched by CD4+ cell counts. CMV was detected by PCR in cerebrospinal fluid (CSF) samples obtained from AIDS patients with CNS disease and from urine and saliva samples obtained from AIDS patients without CNS disease. CMV strains obtained were digested by restriction enzymes HinffI and RsaI to classify the genotypes. The CMV gB genotype was determined in 26 CSF samples. Of these, 11/26 (42.3%) typed as gB group 1, seven (26.9%) as gB2, four (15.4%) as gB3, and four (15.4%) as gB4. The CMV gB genotype frequency distribution in the 42 AIDS patients without CNS disease showed that 18/42 (42.8%) were classified as gB group 1, 10 (23.8%) as gB2, seven (16.6%) as gB3, and seven (16.6%) as gB4. In the present study, no association was found between CMV gB genotypes and CMV‐related central nervous system disease. J. Med. Virol. 71:404–407, 2003. © 2003 Wiley‐Liss, Inc.